Dclk1 distinguishes between tumor and normal stem cells in the intestine
Search this article
Abstract
There is great interest in tumor stem cells (TSCs) as potential therapeutic targets; however, cancer therapies targeting TSCs are limited. A drawback is that TSC markers are often shared by normal stem cells (NSCs)1–4; thus, therapies that target these markers may cause severe injury to normal tissues. To identify a potential TSC-specific marker, we focused on doublecortin-like kinase 1 (Dclk1). Dclk1 was reported as a candidate NSC marker in the gut5, 6, but recent reports have implicated it as a marker of differentiated cells (for example, Tuft cells)7, 8. Using lineage-tracing experiments, we show here that Dclk1 does not mark NSCs in the intestine but instead marks TSCs that continuously produce tumor progeny in the polyps of ApcMin/+ mice. Specific ablation of Dclk1-positive TSCs resulted in a marked regression of polyps without apparent damage to the normal intestine. Our data suggest the potential for developing a therapy for colorectal cancer based on targeting Dclk1-positive TSCs.
Journal
-
- Nature Genetics
-
Nature Genetics 45 (1), 98-103, 2012-12-02
Nature Publishing Group
- Tweet
Details 詳細情報について
-
- CRID
- 1050845760675218560
-
- NII Article ID
- 120004996279
-
- NII Book ID
- AA1084279X
-
- ISSN
- 10614036
- 15461718
- http://id.crossref.org/issn/10614036
-
- DOI
- 10.1038/ng.2481
-
- HANDLE
- 2433/163077
-
- Text Lang
- en
-
- Article Type
- journal article
-
- Data Source
-
- IRDB
- Crossref
- CiNii Articles
- KAKEN